Skip to content

Whitepaper · 2026 Edition

Download CRISPR QC's Latest Whitepaper: Quantifying Off Target Effects & Defining Upper-Dosing Boundaries

A mechanism-linked, quantitative approach to the Upper Dosing Boundary—answering the question every CRISPR program must: how much is too much?

Key Takeaways

  • Off-target risk is often concentration-dependent—raising RNP dose can strengthen on-target editing while increasing unwanted binding and cleavage.
  • Target-specific amplicon chips quantify on-target vs off-target RNP binding affinity, saturation, and ranking across conditions.
  • Mg²⁺-triggered cleavage adds a functional layer—revealing cleavage efficiency, kinetic category, and potency across off-target sequences to help define an upper dosing boundary.
Quantifying Off Target Effects & Defining Upper-Dosing Boundaries whitepaper cover

Why upper dosing boundaries matter

CRISPR programs must balance potency against off-target risk. Without a mechanism-linked readout of how RNPs engage intended and unintended sequences across concentration, dosing decisions stay empirical—and safety margins stay unclear.

This whitepaper outlines a quantitative framework for measuring off-target binding and cleavage behavior so teams can define practical upper dosing boundaries before committing to downstream editing and development decisions.

What the assay measures

  • On-target and off-target RNP capture binding curves from amplicon-immobilized chips
  • Relative off-target binding affinity, saturation, and ranking across RNP conditions
  • Mg²⁺-activated cleavage efficiency and kinetic category (fast/slow) across off-target sequences
  • Data to support upper dosing boundary definition for a given guide, Cas format, and target panel

Applications covered in the paper

  • Comparing on-target vs known or suspected off-target sequences under matched RNP conditions
  • Identifying concentration ranges where on-target engagement is strong while off-target activity remains limited
  • Supporting guide selection, dose justification, and risk assessment with biochemical off-target readouts
  • Informing translational and preclinical development with mechanism-linked upper dosing guidance

Complete the form above to download the full whitepaper and explore the assay framework in detail.